Spirocyclic Piperidine MC2R Antagonists for Selective Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to excessive melanocortin receptor 2 (MC2R) activity, such as Cushing's syndrome and adrenal hyperplasia, often cause unwanted side effects due to non-selective modulation of other melanocortin receptors, necessitating the development of selective MC2R modulators.
Innovation Solution
Development of spirocyclic piperidine compounds that act as selective MC2R antagonists, modulating MC2R activity without affecting other melanocortin receptors, thereby reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective melanocortin receptor modulators are used to treat conditions related to excessive MC2R activity, then therapeutic effect on MC2R is achieved, but unwanted side effects occur due to modulation of other melanocortin receptors
Solution Approach 1:
The patent applies local quality by designing a compound with distinct structural regions that confer selective affinity for MC2R. The spirocyclic piperidine core combined with specific substituent patterns (aryl/heteroaryl groups at defined positions) creates a molecule that interacts preferentially with MC2R binding site characteristics, allowing therapeutic effect on MC2R-mediated conditions while avoiding activation of other melanocortin receptors that have different binding site properties
2Object-affected harmful factors
If selective MC2R antagonists are developed to reduce side effects, then specificity for MC2R is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into functionally distinct segments: a spirocyclic piperidine core structure that provides the fundamental MC2R interaction capability, and specific substituent groups (aryl, heteroaryl, and their substitutions) that fine-tune the selectivity profile. This modular approach allows the compound to achieve high MC2R specificity through the combination of these segments rather than requiring a completely complex structure
Solution Approach 2:
The patent applies composite materials by combining different structural motifs (spirocyclic system, piperidine ring, aryl/heteroaryl substituents) into a single hybrid molecular structure. This composite approach leverages the beneficial properties of each component to achieve both MC2R selectivity and acceptable structural complexity, rather than using a single simple structure that would lack specificity
Data Source
AI summary
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.